克罗恩病研究进展_培训课件.pptVIP

* * Binding of an inflammatory cytokine to its cell surface receptor leads to the production of additional inflammatory mediators. Monoclonal antibodies to inflammatory cytokines prevent cytokines from binding to their cell surface receptors. 1 Choy EHS et al. N Engl J Med. 2001;344:907–16 * In an effort to reduce immunogenicity and increase therapeutic potential, monoclonal antibodies have undergone a type of molecular “evolution” to reduce or eliminate the proportion of murine components. The first monoclonal antibodies used therapeutically were, by nature of the method of their production